ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies.

Published on May 1, 2021in Brachytherapy1.853
· DOI :10.1016/J.BRACHY.2021.01.006
Kelvin Hong29
Estimated H-index: 29
(Johns Hopkins University),
Olaguoke Akinwande8
Estimated H-index: 8
(WashU: Washington University in St. Louis)
+ 15 AuthorsClayton Trimmer1
Estimated H-index: 1
(Baylor University Medical Center)
Sources
Abstract
PURPOSE The American College of Radiology (ACR), American Brachytherapy Society (ABS), American College of Nuclear Medicine (ACNM), American Society for Radiation Oncology (ASTRO), Society of Interventional Radiology (SIR), and Society of Nuclear Medicine and Molecular Imaging (SNMMI) have jointly developed a practice parameter on selective internal radiation therapy (SIRT) or radioembolization for treatment of liver malignancies. Radioembolization is the embolization of the hepatic arterial supply of hepatic primary tumors or metastases with a microsphere yttrium-90 brachytherapy device. MATERIALS AND METHODS The ACR -ABS -ACNM -ASTRO -SIR -SNMMI practice parameter for SIRT or radioembolization for treatment of liver malignancies was revised in accordance with the process described on the ACR website (https://www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters-Interventional and Cardiovascular Radiology of the ACR Commission on Interventional and Cardiovascular, Committee on Practice Parameters and Technical Standards-Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with ABS, ACNM, ASTRO, SIR, and SNMMI. RESULTS This practice parameter is developed to serve as a tool in the appropriate application of radioembolization in the care of patients with conditions where indicated. It addresses clinical implementation of radioembolization including personnel qualifications, quality assurance standards, indications, and suggested documentation. CONCLUSIONS This practice parameter is a tool to guide clinical use of radioembolization. It focuses on the best practices and principles to consider when using radioemboliozation effectively. The clinical benefit and medical necessity of the treatment should be tailored to each individual patient.
📖 Papers frequently viewed together
1 Citations
7 Citations
References54
Newest
#1Robert J. Lewandowski (NU: Northwestern University)H-Index: 68
#2Ahmed Gabr (NU: Northwestern University)H-Index: 15
Last. Riad SalemH-Index: 92
view all 16 authors...
Radiation segmentectomy provides local tumor control, prolonged time to progression, and overall survival outcomes comparable to radiofrequency ablation, resection, and transplantation for Barcelona Clinic Liver Cancer stage 0 or A patients. This treatment should be further investigated as a potentially curative treatment in patients not amenable to standard options.
81 CitationsSource
#1Pierce K. H. Chow (NUS: National University of Singapore)H-Index: 69
#2Mihir Gandhi (NUS: National University of Singapore)H-Index: 17
Last. Khee Chee SooH-Index: 59
view all 41 authors...
PurposeSelective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC.Patients and MethodsSIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (90Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced H...
250 CitationsSource
#1Valérie Vilgrain (French Institute of Health and Medical Research)H-Index: 95
#2Helena Pereira (French Institute of Health and Medical Research)H-Index: 11
Last. Lysiane MartheyH-Index: 14
view all 107 authors...
Summary Background Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ( 90 Y) resin microspheres in patients with hepatocellular carcinoma. Methods SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if th...
335 CitationsSource
#1Siddharth A. Padia (UCLA: University of California, Los Angeles)H-Index: 12
#2Guy E. Johnson (UW: University of Washington)H-Index: 11
Last. William P. Harris (UW: University of Washington)H-Index: 22
view all 12 authors...
Abstract Purpose To compare segmental radioembolization with segmental chemoembolization for localized, unresectable hepatocellular carcinoma (HCC) not amenable to ablation. Materials and Methods In a single-center, retrospective study (2010–2015), 101 patients with 132 tumors underwent segmental radioembolization, and 77 patients with 103 tumors underwent segmental doxorubicin-based drug-eluting embolic or conventional chemoembolization. Patients receiving chemoembolization had worse performanc...
42 CitationsSource
#1D. Biederman (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 8
#2Joseph J. Titano (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 9
Last. Edward Kim (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 17
view all 10 authors...
Our study demonstrates similar short-term effectiveness of radiation segmentectomy and transarterial chemoembolization combined with microwave ablation in the treatment of unresectable solitary hepatocellular carcinoma up to 3 cm, with both modalities appearing to be capable of achieving favorable imaging response and progression outcomes.
46 CitationsSource
#1Siddharth A. Padia (UCLA: University of California, Los Angeles)H-Index: 12
#2Robert J. Lewandowski (NU: Northwestern University)H-Index: 68
Last. Riad Salem (NU: Northwestern University)H-Index: 92
view all 16 authors...
63 CitationsSource
#1Julien Edeline (French Institute of Health and Medical Research)H-Index: 29
#2Laurence CrouzetH-Index: 6
Last. Etienne Garin (French Institute of Health and Medical Research)H-Index: 31
view all 14 authors...
Purpose Tumoural portal vein thrombosis (PVT) is a major prognostic factor in hepatocellular carcinoma (HCC). The efficacy of sorafenib, the only treatment approved at an advanced stage, is limited. Based on previous data, selective internal radiation therapy (SIRT), or 90Y radioembolization, seems an interesting option. We aimed to compare both treatments in this population.
57 CitationsSource
#1Etienne GarinH-Index: 31
#2Yan RollandH-Index: 25
Last. Eveline BoucherH-Index: 34
view all 14 authors...
The objective of this study was to evaluate the response rate and survival of hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with (90)Y-loaded glass microspheres using a personalized dosimetry and intensification concept. The microspheres were administered to 41 hepatocellular carcinoma PVT patients (main = 12; lobar/segmental = 29). (99m)Tc-macroaggregated albumin SPECT/CT quantitative analysis was used to calculate the tumor dose (TD), healthy injected liver dose (HILD)...
86 CitationsSource
#1Michael VoucheH-Index: 16
#2Ali HabibH-Index: 14
Last. Riad SalemH-Index: 92
view all 16 authors...
Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular carcinoma (HCC) <3 cm; there is interest in expanding the role of ablation to 3-5 cm. RFA is considered high-risk when the lesion is in close proximity to critical structures. Combining microcatheter technology and the localized emission properties of Y90, highly selective radioembolization is a possible alternative to RFA in such cases. We assessed the efficacy (response, radiology-pathology correlation, surviv...
158 CitationsSource
#1Yung Hsiang Kao (SGH: Singapore General Hospital)H-Index: 11
#2Butch Magsombol (SGH: Singapore General Hospital)H-Index: 4
Last. David Ce Ng (SGH: Singapore General Hospital)H-Index: 4
view all 7 authors...
Background For yttrium-90 (90Y) radioembolization, the common practice of assuming a standard 1,000-g lung mass for predictive dosimetry is fundamentally incongruent with the modern philosophy of personalized medicine. We recently developed a technique of personalized predictive lung dosimetry using technetium-99m (99mTc) macroaggregated albumin (MAA) single photon emission computed tomography with integrated CT (SPECT/CT) of the lung as part of our routine dosimetric protocol for 90Y radioembol...
31 CitationsSource
Cited By2
Newest
#2Bin QiuH-Index: 1
Last. Junjie Wang (PKU: Peking University)H-Index: 3
view all 8 authors...
Brachytherapy (BT), a type of focal anti-cancer radiotherapy, delivers a highly focused radiation dose to localized tumors, sparing surrounding normal tissues. Recent technological advances have helped to increase the accuracy of BT and, thus, improve BT-based cancer treatment. Stereotactic ablative brachytherapy (SABT) was designed to improve the ablative effect of radiation, which was achieved via improved image guidance, and calculation of ablative dose, shorter treatment duration, and better...
Source
#7Yi Jen Chen (City of Hope National Medical Center)H-Index: 3
Source